Apellis Pharmaceuticals ( (APLS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Apellis Pharmaceuticals’ stock is on the rise after Wells Fargo upgraded the company to an Overweight rating. This positive shift comes as analysts express confidence in the stabilizing sales of Syfovre and the promising launch of Empaveli. The shares are anticipated to rally by 15%-20% due to expected growth in Empaveli, highlighting the company’s long-term growth potential despite existing challenges.
More about Apellis Pharmaceuticals
YTD Price Performance: -30.19%
Average Trading Volume: 2,461,125
Technical Sentiment Signal: Hold
Current Market Cap: $3.05B
For further insights into APLS stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.